Skip to main content

About sotrovimab (Xevudy)

Sotrovimab is a biological medicine. It's also known as a neutralising monoclonal antibody (nMAb). It's used to treat coronavirus (COVID-19).

nMAbs are synthetic proteins that act like human antibodies in the immune system. They are made by cloning an antibody that can stick to the spike protein of the virus and neutralise it. They stick to the virus and stop it from getting into your lungs and causing an infection.

If you are eligible for COVID-19 treatment you will usually be offered neutralising monoclonal antibodies (nMAbs) such as sotrovimab as a first treatment rather than antiviral medicines.

It's usually given to you through a drip in your arm (infusion). It will be given in hospital or at a local centre.

If you have tested positive for COVID-19, are self-isolating, and are eligible, you will get instructions on where you'll have the treatment, and how to get there and back safely.

Key facts

  • Sotrovimab will keep working in your body and help prevent reinfection from COVID-19 for at least 4 weeks.
  • The dose of sotrovimab is 500mg. It's given to your through a drip in your arm (infusion) over 30 minutes. You'll only need 1 dose.
  • The most common side effects include feeling sick, feeling dizzy, an itchy rash or redness or warmth on your skin.
  • If you feel dizzy after your treatment, do not drive a car, ride a bike, or use tools or machinery.

Page last reviewed: 20 December 2021
Next review due: 20 December 2024